CARISMA THERAP (CARM)
(Delayed Data from NSDQ)
$0.95 USD
-0.03 (-2.86%)
Updated Oct 1, 2024 04:00 PM ET
After-Market: $0.95 0.00 (-0.37%) 7:58 PM ET
2-Buy of 5 2
F Value D Growth D Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
CARM 0.95 -0.03(-2.86%)
Will CARM be a Portfolio Killer in October?
Zacks Investment Research is releasing its prediction for CARM based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CARM
CARISMA THERAP (CARM) Upgraded to Buy: What Does It Mean for the Stock?
Carisma Therapeutics Inc. (CARM) Reports Q2 Loss, Tops Revenue Estimates
CARM: What are Zacks experts saying now?
Zacks Private Portfolio Services
Carisma Therapeutics Inc. (CARM) Reports Q1 Loss, Misses Revenue Estimates
Carisma Therapeutics Inc. (CARM) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
Here's Why CARISMA THERAP (CARM) Is a Great 'Buy the Bottom' Stock Now
Other News for CARM
Catalyst Watch: Tesla deliveries, Nike earnings, port strike threat and the jobs report
Successful Completion of Tender Offer on Carmila?s Bonds With ?200,100,000 of Bonds Tendered
Carmila Successfully Issues Inaugural ?300M 7-Year Green Bond, Paying a Fixed Annual Coupon of 3.875%
Carmila Announces the Launch of a Tender Offer on Its Existing Notes Maturing in May 2027, March 2028, October 2028 and April 2029, and Announces Its Intention to Issue New Notes
Carisma Therapeutics and Moderna expand collaboration to develop CAR-M therapies